VBI Vaccines Inc (VBIV) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
VBI Vaccines Inc. has reported a significant year-over-year revenue increase of 234% for its PreHevbrio Hepatitis B vaccine, with U.S. sales in the first quarter of 2024 already accounting for 65% of the full-year volume of 2023. Positive clinical trial results for VBI-1901 in treating recurrent glioblastoma show potential, with further data expected later in the year. Amid financial market challenges, the company has improved financial stability by strengthening its balance sheet and reducing debt, aiming for sustainable growth and stakeholder value.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue